Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 14/20 | 0.78 |
| ▸ | ESR1 | P03372 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.67 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.67 |
| ▸ | SHBG | P04278 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.67 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.67 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27488647 | 0.92 | STS (0.78) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL9404855 | 0.90 | STS (0.75) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL15228405 | 0.88 | STS (0.60) | STSESR1ESR2MEN1KMT2A | |
| SCHEMBL9404747 | 0.88 | STS (0.78) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL4903619 | 0.88 | STS (1.00) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL4903623 | 0.88 | STS (1.00) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL486651 | 0.87 | STS (0.79) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL14515129 | 0.87 | STS (0.85) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL2517116 | 0.87 | STS (0.61) | STSESR1CYP3A4ESR2SLC22A2 | |
| SCHEMBL31508217 | 0.85 | STS (0.81) | STSESR1CYP3A4ESR2SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190269616-A1 | STERILE PARENTERAL SUSPENSIONS | EMCURE PHARMACEUTICALS LIMITED (IN) | 2019-09-05 | — | — | US | claimed |
| EP-3386483-A1 | STERILE PARENTERAL SUSPENSIONS | Emcure Pharmaceuticals Limited (IN) | 2018-10-17 | — | — | EP | claimed |
| WO-2017098392-A1 | STERILE PARENTERAL SUSPENSIONS | EMCURE PHARMACEUTICALS LIMITED (IN) | 2017-06-15 | — | — | WO | claimed |
| US-20170087099-A1 | TRANSDERMAL SYSTEMS CONTAINING MULTILAYER ADHESIVE MATRICES TO MODIFY DRUG DELIVERY | MYLAN TECH INC (US) | 2017-03-30 | — | — | US | claimed |
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | MACRO CHEM CORPORATION | 2007-12-13 | — | — | US | claimed |
| WO-2007117352-A2 | TOPICAL THERAPEUTIC DELIVERY SYSTEM | MURAD HOWARD (US) | 2007-10-18 | — | — | WO | claimed |
| EP-1648364-A2 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION | MacroChem Corporation (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005007100-A2 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION | MACROCHEM CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| EP-0269696-B1 | TRANSDERMAL ABSORPTION DOSAGE UNIT FOR ESTRADIOL AND OTHER ESTROGENIC STEROIDS | UNIV RUTGERS (US) | 1994-08-03 | — | — | EP | claimed |
| US-3962430-A | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | claimed |
| US-20230057790-A1 | INJECTABLE CONTROLLED-RELEASE FORMULATIONS OF PROGESTOGEN DRUGS | FORDOZ PHARMA CORP. (US) | 2023-02-23 | — | — | US | disclosed |
| CN-115605187-A | Injectable controlled release formulation loaded with progestagen drug | 福多兹制药公司（US） | 2023-01-13 | — | — | CN | disclosed |
| CN-109475138-B | Multifunctional structured glycidol/non-glycidol materials | 美国AAK公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-114522152-A | Use of antistatic materials in airways for hot aerosol condensation processes | 艾利斯达医药品公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-114522307-A | Use of antistatic materials in airways for hot aerosol condensation processes | 艾利斯达医药品公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-0275716-A1 | Transdermal estrogen/progestin dosage unit, and fertility control kit comprising said dosage unit. | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1988-07-27 | — | — | EP | disclosed |
| EP-0269696-A1 | TRANSDERMAL ABSORPTION DOSAGE UNIT FOR ESTRADIOL AND OTHER ESTROGENIC STEROIDS. | UNIV NEW JERSEY (US) | 1988-06-08 | — | — | EP | disclosed |
| WO-1988001496-A1 | TRANSDERMAL FERTILITY CONTROL SYSTEM AND PROCESS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1988-03-10 | — | — | WO | disclosed |
| WO-1987007138-A1 | TRANSDERMAL ABSORPTION DOSAGE UNIT FOR ESTRADIOL AND OTHER ESTROGENIC STEROIDS AND PROCESS FOR ADMINISTRATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1987-12-03 | — | — | WO | disclosed |
| US-3962430-A | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | CYP8B1, NR1H3, NR1H2 | STS 1000/4885ESR1 1994/4885CYP3A4 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.